Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.38 |
| ▸ | DNM1 | Q05193 | 1/20 | 0.37 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.37 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.37 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.36 |
| ▸ | USP2 | O75604 | 1/20 | 0.36 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.36 |
| ▸ | LMNA | P02545 | 1/20 | 0.36 |
| ▸ | UTS2R | Q9UKP6 | 3/20 | 0.35 |
| ▸ | PKM | P14618 | 2/20 | 0.35 |
| ▸ | SIGMAR1 | Q99720 | 2/20 | 0.35 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.35 |
| ▸ | POLB | P06746 | 1/20 | 0.35 |
| ▸ | RECQL | P46063 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31413299 | 0.81 | LMNA (0.43) | ALDH1A1LMNAPKMPOLBRECQL | |
| SCHEMBL26812175 | 0.79 | L3MBTL1 (0.38) | ALDH1A1KDM4EKMT2AMAPK1SIGMAR1 | |
| SCHEMBL16103858 | 0.79 | L3MBTL1 (0.38) | ALDH1A1KDM4EKMT2AMAPK1SIGMAR1 | |
| SCHEMBL31622466 | 0.76 | DNM1 (0.42) | ALDH1A1DNM1KDM4ESMN1; SMN2USP2 | |
| SCHEMBL4280071 | 0.74 | ALDH1A1 (0.70) | ALDH1A1DNM1KDM4EKMT2ASMN1; SMN2 | |
| SCHEMBL27353549 | 0.74 | LTA4H (0.35) | ALDH1A1PKMSIGMAR1POLB | |
| SCHEMBL1008457 | 0.72 | POLB (0.46) | ALDH1A1KDM4ESMN1; SMN2PKMPOLB | |
| SCHEMBL15707100 | 0.72 | POLB (0.46) | ALDH1A1KDM4ESMN1; SMN2PKMPOLB | |
| SCHEMBL1007721 | 0.72 | POLB (0.46) | ALDH1A1KDM4ESMN1; SMN2PKMPOLB | |
| SCHEMBL29300261 | 0.72 | SIGMAR1 (0.42) | ALDH1A1KDM4EKMT2ASMN1; SMN2LMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260049072-A1 | HETEROCYCLIC COMPOUND FOR INDUCING DEGRADATION OF MUTANT KRAS PROTEIN | ASTELLAS PHARMA INC (JP) | 2026-02-19 | — | — | US | disclosed |
| EP-4567033-A1 | HETEROCYCLIC COMPOUND FOR INDUCING DEGRADATION OF MUTANT KRAS PROTEIN | Astellas Pharma Inc. (JP) | 2025-06-11 | — | — | EP | disclosed |
| WO-2024261256-A1 | PHARMACEUTICAL COMPOSITION COMPRISING A pan-KRAS DEGRADER | ASTELLAS PHARMA INC. (JP) | 2024-12-26 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20260049072-A1 | HETEROCYCLIC COMPOUND FOR INDUCING DEGRADATION OF MUTANT KRAS PROTEIN | KRAS, NRAS, HRAS | ALDH1A1 4200/4885DNM1 1029/4885KDM4E 2935/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.